Jupiter Neurosciences Launches Consumer Longevity Line Nugevia Using Patented JOTROL Technology
Jupiter Neurosciences introduces Nugevia, a direct-to-consumer product line leveraging its clinically proven JOTROL formulation to address mitochondrial health, cognitive function, and skin benefits while generating revenue alongside pharmaceutical development.
Jupiter Neurosciences Inc. has launched Nugevia, a direct-to-consumer product line utilizing its patented JOTROL technology, marking a strategic expansion into the growing longevity market while maintaining its pharmaceutical development focus. The company's leadership emphasized that this move addresses both consumer demand for scientifically-backed supplements and the need for revenue generation in the biotech sector.
The core innovation behind both JOTROL and Nugevia lies in Jupiter Neurosciences' ability to overcome longstanding limitations of resveratrol supplementation. As President Alison Silva explained, achieving therapeutic benefits requires plasma concentrations exceeding 250 nanograms per milliliter, which conventional products cannot deliver without causing severe gastrointestinal side effects or requiring impractical dosing. Clinical trials demonstrated that JOTROL achieves blood plasma levels 8-10 times higher than standard resveratrol with one-tenth the dose, all without gastrointestinal complications.
This technological breakthrough enables the company to target multiple markets simultaneously. While JOTROL continues development for central nervous system disorders including Alzheimer's and Parkinson's disease through clinical trials, the Nugevia line immediately addresses consumer needs for mitochondrial support, cognitive enhancement, and skin health. The three initial formulations include Nugevia GLO for cellular defense and collagen integrity, Nugevia PWR for mitochondrial health and energy support, and Nugevia MND for cognitive function protection.
CEO Christer Rosen highlighted the revenue strategy behind the consumer launch, noting that while pharmaceutical development remains the primary focus, the direct-to-consumer model provides essential cash flow. The company has secured professional golfer Annika Sörenstam as its first brand ambassador, with additional partnerships expected to drive market awareness and sales growth beginning this year and accelerating through 2026. Rosen also addressed short seller pressure on the company's stock, expressing confidence that clinical and commercial execution will ultimately determine market valuation.
The launch positions Jupiter Neurosciences at the intersection of pharmaceutical innovation and consumer health markets, leveraging patented technology through 2036 to address both therapeutic needs and preventive health strategies in the rapidly expanding longevity sector.